BioRestorative Therapies, Inc.
BRTXNASDAQHealthcare● Active
$0.36
$-0.04(-10.62%)
Market Cap$3255285
P/E Ratio—
52W High$2.045
52W Low$0.1593
BioRestorative Therapies, Inc. (BRTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BRTX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.19
Est. -$0.30 · +36.7%
Revenue
$0.00B
Est. $0.00B · +0.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat EPS🔥 4-Quarter EPS Beat Streak
BRTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.15 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 14, 2026 | -$0.30 | -$0.19 | +36.7% | $0.00B | $0.00B | +0.0% |
| — Q1 FY2026 | Mar 26, 2026 | -$0.37 | -$0.37 | +0.0% | $0.00B | $0.00B | -86.7% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.36 | -$0.33 | +8.3% | $0.00B | $0.00B | -97.4% |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.41 | -$0.30 | +26.8% | $0.00B | $0.00B | +51.6% |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.32 | -$0.56 | -75.0% | $0.00B | $0.00B | -93.4% |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.27 | -$0.20 | +25.9% | $0.00B | $0.00B | -90.9% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.43 | -$0.13 | +69.8% | $0.00B | $0.00B | -50.8% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Beat
EPS Actual
-$0.19
EPS Est.
-$0.30
EPS Surpr.
+36.7%
Revenue
$0.00B
Q1 FY2026
Mar 26, 2026
EPS Actual
-$0.37
EPS Est.
-$0.37
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.33
EPS Est.
-$0.36
EPS Surpr.
+8.3%
Revenue
$0.00B
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.30
EPS Est.
-$0.41
EPS Surpr.
+26.8%
Revenue
$0.00B
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$0.56
EPS Est.
-$0.32
EPS Surpr.
-75.0%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$0.27
EPS Surpr.
+25.9%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.13
EPS Est.
-$0.43
EPS Surpr.
+69.8%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +36.7% | $0.19 | $0.19 | +1.56% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +0.0% | $0.31 | $0.30 | -4.52% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +8.3% | $1.41 | $1.38 | -2.13% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +26.8% | $1.41 | $1.47 | +4.26% |
| ▼ Q2 FY2025 | May 14, 2025 | -75.0% | $1.71 | $1.71 | +0.00% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +25.9% | $1.76 | $1.83 | +3.98% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +69.8% | $1.65 | $1.64 | -0.61% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +10.7% | $1.43 | $1.41 | -1.40% |
Q2 FY2026+1.56%
Report Date
May 14, 2026
EPS Beat/Miss
+36.7%
Price Before
$0.19
Price After
$0.19
Q1 FY2026-4.52%
Report Date
Mar 26, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.31
Price After
$0.30
Q4 FY2025-2.13%
Report Date
Nov 12, 2025
EPS Beat/Miss
+8.3%
Price Before
$1.41
Price After
$1.38
Q3 FY2025+4.26%
Report Date
Aug 12, 2025
EPS Beat/Miss
+26.8%
Price Before
$1.41
Price After
$1.47
Q2 FY2025+0.00%
Report Date
May 14, 2025
EPS Beat/Miss
-75.0%
Price Before
$1.71
Price After
$1.71
Q1 FY2025+3.98%
Report Date
Mar 27, 2025
EPS Beat/Miss
+25.9%
Price Before
$1.76
Price After
$1.83
Q4 FY2024-0.61%
Report Date
Nov 12, 2024
EPS Beat/Miss
+69.8%
Price Before
$1.65
Price After
$1.64
Q3 FY2024-1.40%
Report Date
Aug 13, 2024
EPS Beat/Miss
+10.7%
Price Before
$1.43
Price After
$1.41
Avg Beat Reaction+0.16%
Avg Miss Reaction+0.00%
Beat Rate7 / 8 quarters
Largest Move-4.52% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BRTX ends December
BioRestorative Therapies, Inc. (BRTX) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.19 — beating the analyst consensus of $-0.30 by +36.7%. BRTX has beaten EPS estimates for 4 consecutive quarters. The next BRTX earnings date is expected around September 1, 2026.
Each quarter, investors track BRTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BRTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BRTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BRTX earnings · 5 questionsBioRestorative Therapies, Inc.'s next earnings report is expected around September 1, 2026. BRTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BRTX historically reports after market close (AMC).
BRTX earnings datewhen is BRTX earningsBRTX next earnings datewhen does BRTX report earningsBRTX earnings calendar
▸ Source: FMP · BioRestorative Therapies, Inc. SEC filings · US GAAP · BioRestorative Therapies, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026